Show simple item record

dc.contributor.authorWolpin, Brian M.
dc.contributor.authorNg, Kimmie
dc.contributor.authorBao, Ying
dc.contributor.authorKraft, Peter
dc.contributor.authorStampfer, Meir
dc.contributor.authorMichaud, Dominique S.
dc.contributor.authorMa, Jing
dc.contributor.authorBuring, Julie E.
dc.contributor.authorSesso, Howard D.
dc.contributor.authorLee, I-Min
dc.contributor.authorRifai, Nader
dc.contributor.authorCochrane, Barbara B.
dc.contributor.authorWactawski-Wende, Jean
dc.contributor.authorChlebowski, Rowan T.
dc.contributor.authorWillett, Walter C.::94559ea206eef8a8844fc5b80654fa5b::600
dc.contributor.authorManson, JoAnn E.
dc.contributor.authorGiovannucci, Edward L.
dc.contributor.authorFuchs, Charles S.
dc.date.accessioned2019-09-05T17:03:57Z
dc.date.issued2012
dc.identifier.citationWolpin, B. M., K. Ng, Y. Bao, P. Kraft, M. J. Stampfer, D. S. Michaud, J. Ma, et al. 2011. “Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer.” Cancer Epidemiology Biomarkers & Prevention 21 (1): 82–91. https://doi.org/10.1158/1055-9965.epi-11-0836.
dc.identifier.issn1055-9965
dc.identifier.issn1538-7755
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:41292494*
dc.description.abstractBackground: Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting. Methods: To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH) D. Results: Mean plasma 25(OH) D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH) D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97; P(trend) = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH] D, < 50 nmol/L], ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency [25[OH] D, 50 to <75 nmol/L] and 0.71 (0.52-0.97) for those with sufficient levels [25[OH] D, >= 75 nmol/L]. No increased risk was noted in subjects with 25(OH) D >= 100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH) D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites. Conclusions: Among participants in five large prospective cohorts, higher plasma levels of 25(OH) D were associated with a lower risk for pancreatic cancer.Impact: Low circulating 25(OH) D may predispose individuals to the development of pancreatic cancer. Cancer Epidemiol Biomarkers Prev; 21(1); 82-91.
dc.language.isoen_US
dc.publisherAmerican Association for Cancer Research
dash.licenseLAA
dc.titlePlasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer
dc.typeJournal Article
dc.description.versionAccepted Manuscript
dc.relation.journalCancer Epidemiology, Biomarkers & Prevention
dash.depositing.authorStampfer, Meir
dc.date.available2019-09-05T17:03:57Z
dash.workflow.comments1Science Serial ID 26464
dc.identifier.doi10.1158/1055-9965.EPI-11-0836
dash.source.volume21;1
dash.source.page82
dash.contributor.affiliatedStampfer, Meir


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record